Skip to content

BridgeBio Pharma BBIO Cash Flow Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$729.89M+0.4%-$732.94M+9.0%-$805.69M-2.6%-$785.01M-16.0%-$676.8M-24.6%
$5.34M-1.8%$5.43M+1.3%$5.37M-2.5%$5.51M-4.5%$5.76M-5.1%
$140.38M+5.5%$133.02M+3.5%$128.51M+6.7%$120.41M+15.1%$104.63M+9.2%
-$443.95M+0.4%-$445.91M+23.8%-$584.82M+10.8%-$655.81M
$1.17M+6.3%$1.1M-1.3%$1.11M+42.8%$778K+227%$238K-74.5%
$23.63M-40.4%$39.67M-38.0%
$48.28M
$837.01M+56.5%$534.97M-29.1%
$339.28M+405%-$111.1M-147%$237.22M
-$445.12M+0.4%-$447.01M+23.7%-$585.93M+10.8%-$656.59M

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does BridgeBio Pharma generate?
BridgeBio Pharma (BBIO) generated -$444.0M in operating cash flow over the trailing twelve months.
What is BridgeBio Pharma's free cash flow?
After $1.2M of capital expenditures, BridgeBio Pharma's free cash flow was -$445.1M over the trailing twelve months, up 44.0% year over year.
Where does BridgeBio Pharma's cash flow data come from?
Every line is extracted from BridgeBio Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.